Phase 2/3 trial in 315 patients with first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma: adding feladilimab to pembrolizumab showed no benefit vs placebo (adjusted HR 1.51 for OS, 1.40 for PFS); accrual stopped after an interim review.
RCTn = 315
Rischin et al. INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma